Abstract
The A Disintegrin And Metalloprotease (ADAM) proteins belong to the metzincin-superfamily of Zndependent metalloproteinases that shed the extracellular domains of membrane-bound growth factors, cytokines and their receptors. The latter play a central role in cell signaling and contribute a potential target in cancer therapy. Of particular interest are the ErBB/HER family of growth factor receptors associated with elevated intrinsic tyrosine kinase activity. Overexpression of ADAMs and cell signaling components have also been implicated in the development and progression of a variety of tumor types. Emerging evidence has suggested that the ADAM proteins are involved in tumour cell proliferation, in angiogenesis as well as metastasis. Therefore, strategies targeting ADAMs may constitute an important target for the design of cancer drugs. The review will focus on current understanding of the role of ADAM in the physiological and pathological functions associated with cancer. It is the intention of the review to provide insights which may assist in the development of ADAM-based approaches for the treatment of human cancers.
Keywords: ADAM protein, disintegrins, RGD motif, integrin, disintegrin-like domain, VEGFR, ERBB receptor
Current Cancer Drug Targets
Title: ADAM Proteins- Therapeutic Potential in Cancer
Volume: 8 Issue: 8
Author(s): Xinjie Lu, Dong Lu, Mike Scully and Vijay Kakkar
Affiliation:
Keywords: ADAM protein, disintegrins, RGD motif, integrin, disintegrin-like domain, VEGFR, ERBB receptor
Abstract: The A Disintegrin And Metalloprotease (ADAM) proteins belong to the metzincin-superfamily of Zndependent metalloproteinases that shed the extracellular domains of membrane-bound growth factors, cytokines and their receptors. The latter play a central role in cell signaling and contribute a potential target in cancer therapy. Of particular interest are the ErBB/HER family of growth factor receptors associated with elevated intrinsic tyrosine kinase activity. Overexpression of ADAMs and cell signaling components have also been implicated in the development and progression of a variety of tumor types. Emerging evidence has suggested that the ADAM proteins are involved in tumour cell proliferation, in angiogenesis as well as metastasis. Therefore, strategies targeting ADAMs may constitute an important target for the design of cancer drugs. The review will focus on current understanding of the role of ADAM in the physiological and pathological functions associated with cancer. It is the intention of the review to provide insights which may assist in the development of ADAM-based approaches for the treatment of human cancers.
Export Options
About this article
Cite this article as:
Lu Xinjie, Lu Dong, Scully Mike and Kakkar Vijay, ADAM Proteins- Therapeutic Potential in Cancer, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733478
DOI https://dx.doi.org/10.2174/156800908786733478 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Epigenetics in Brain Tumors: HDACs Take Center Stage
Current Neuropharmacology Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Central Nervous System Neoplasms in Hong Kong: An Inscription of Local Studies
Current Cancer Therapy Reviews Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery The Ever Changing Treatments for Tumors of the Central Nervous System
Current Cancer Therapy Reviews Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics Trends and Topics in CD133 in Pubmed From 2000 to 2015
Current Biomarkers (Discontinued) Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance
Current Medicinal Chemistry - Anti-Cancer Agents Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Anti-Cancer Activity of Nitrones and Observations on Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Selection: Mitochondrial Dysfunction & Neurological Disorders)
Current Neuropharmacology Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging